8.61
전일 마감가:
$7.69
열려 있는:
$7.57
하루 거래량:
1.70M
Relative Volume:
2.13
시가총액:
$408.83M
수익:
$8.78M
순이익/손실:
$-104.70M
주가수익비율:
-3.6329
EPS:
-2.37
순현금흐름:
$-82.68M
1주 성능:
+13.89%
1개월 성능:
+5.64%
6개월 성능:
-31.56%
1년 성능:
-28.55%
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
STOK
Stoke Therapeutics Inc
|
8.61 | 408.83M | 8.78M | -104.70M | -82.68M | -2.37 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-20 | 개시 | Chardan Capital Markets | Buy |
2024-10-14 | 재개 | Leerink Partners | Outperform |
2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
2023-11-20 | 재개 | JP Morgan | Neutral |
2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
2023-04-26 | 재개 | Canaccord Genuity | Buy |
2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2022-01-31 | 개시 | Jefferies | Buy |
2021-12-03 | 개시 | BofA Securities | Buy |
2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-05-18 | 개시 | UBS | Neutral |
2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
2020-12-15 | 재개 | H.C. Wainwright | Buy |
2020-12-11 | 재확인 | Needham | Buy |
2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
2020-09-29 | 재개 | JP Morgan | Neutral |
2020-09-29 | 개시 | Needham | Buy |
2019-12-18 | 개시 | Wedbush | Outperform |
2019-11-12 | 개시 | BTIG Research | Buy |
2019-10-25 | 개시 | H.C. Wainwright | Buy |
2019-07-15 | 개시 | Canaccord Genuity | Buy |
2019-07-15 | 개시 | Cowen | Outperform |
2019-07-15 | 개시 | Credit Suisse | Outperform |
2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics Inc (STOK) rating initates by Chardan Capital Markets - knoxdaily.com
(STOK) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Leerink Partnrs Issues Optimistic Estimate for STOK Earnings - Defense World
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be - simplywall.st
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts - Defense World
Vanguard Group Inc. Sells 28,049 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Wellington Management Group LLP Has $1.49 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Needham & Company LLC Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK) - Defense World
Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges - Investing.com India
Teacher Retirement System of Texas Purchases Shares of 10,219 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
Revolutionary RNA Treatment for Rare Disease: Stoke CEO to Reveal Latest Progress - Stock Titan
Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
FY2025 Earnings Forecast for STOK Issued By Chardan Capital - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com Australia
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Brokers Offer Predictions for STOK Q3 Earnings - Defense World
What is Leerink Partnrs’ Forecast for STOK Q1 Earnings? - Defense World
Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush - Defense World
Stoke Therapeutics general counsel sells shares totaling $35,731 By Investing.com - Investing.com South Africa
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital - Defense World
Stoke Therapeutics general counsel sells shares totaling $35,731 - Investing.com Australia
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Issue Forecasts for STOK Q1 Earnings - Defense World
Stoke therapeutics’ chief medical officer sells $61,238 in stock By Investing.com - Investing.com South Africa
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 - Investing.com
Stoke Therapeutics Executives Sell Shares for Tax Liabilities - TradingView
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 By Investing.com - Investing.com UK
Stoke therapeutics’ chief medical officer sells $61,238 in stock - Investing.com
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media
After Securing Biogen Pact, Stoke’s CEO Edward Kaye Bows Out - insights.citeline.com
Stoke Therapeutics announces CEO transition - The Pharma Letter
Stoke Therapeutics Inc (STOK) Q4 Earnings: EPS of -$0.18 Beats E - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Stoke Therapeutics, Inc. SEC 10-K Report - TradingView
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics - Benzinga
Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals
Stoke Therapeutics Slips as CEO Steps Down - MSN
Stoke Therapeutics falls as CEO steps down amid earnings beat By Investing.com - Investing.com Canada
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):